Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
McInnes IB., Sewerin P., Sharaf M., Efficace M., Lavie F., Zimmermann M., Coates LC.